Nascobal Spray
NDC Package 49884-270-82

11-digit billing NDC: 49884027082 · Billing unit: EA · 4 EA per package

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Nascobal (cyanocobalamin) sprays is nASCOBAL is indicated for:Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvementTreatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemiaPrevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use NASCOBAL should not be used for the vitamin B12 absorption test (Schilling test).In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long-term use of NASCOBAL following adequate correction of vitamin B12 deficiency and underlying disease has not been established. This formulation utilizes a spray delivery system. Marketed by Par Health Usa, Llc, this product is identified by NDC 49884-270 and is authorized under FDA application NDA021642.

Identification & Billing

NDC Package Code
49884-270-82
Package Description
4 SPRAY in 1 CARTON
Product Code
11-Digit Billing Format
49884027082
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
4 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Nascobal
Non-Proprietary Name
Cyanocobalamin
Substance Name
Cyanocobalamin
Dosage Form
Spray - A liquid minutely divided as by a jet of air or steam.
Administration Route
Nasal - Administration to the nose; administered by way of the nose.
Active Ingredient(s)
Usage Information
NASCOBAL is indicated for:Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvementTreatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemiaPrevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use NASCOBAL should not be used for the vitamin B12 absorption test (Schilling test).In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long-term use of NASCOBAL following adequate correction of vitamin B12 deficiency and underlying disease has not been established. The effectiveness of NASCOBAL in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with NASCOBAL should be deferred until symptoms have subsided.

Regulatory & Marketing

Labeler Name
Par Health Usa, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021642
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-13-2009
End Marketing Date
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (49884-270). Click a package code to view its specific billing and regulatory data.

1 SPRAY in 1 CARTON
4 SPRAY in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49884-270-82 identifies a specific commercial package of 4 spray in 1 carton of Nascobal, a human prescription drug labeled by Par Health Usa, Llc. This spray is formulated for nasal use and contains cyanocobalamin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Par Health Usa, Llc on August 13, 2009.

How is this Par Health Usa, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49884027082. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49884-270-82
11-Digit CMS (5-4-2)
49884-0270-82

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.